CytRx
Corporation (NASDAQ: CYTR), a biopharmaceutical research and
development company specializing in oncology, today announced that
President and CEO Steven A. Kriegsman and Vice President of Business
Development David J. Haen will present at the 6th Annual LD
MICRO “Main Event” Conference on Tuesday, December 3rd, 2013
at 4:00 p.m. Pacific time. The conference is being held at the Luxe
Sunset Bel Air Hotel in Los Angeles.
Mr. Kriegsman and Mr. Haen will be available for one-on-one meetings
with the investment community on Tuesday, December 3rd.
Please contact LD Micro organizers if you would like to arrange a
meeting.
Interested parties can access the audio webcast with slide presentation
at http://www.cytrx.com/investors/presentations.
An archived presentation will be available for 90 days.
About LD MICRO
LD MICRO is an investment newsletter firm that focuses on finding
undervalued companies in the micro-cap space. Since 2002, the firm has
published an annual list of recommended stocks, as well as comprehensive
reports on select companies throughout the year. The firm also hosts the
LD MICRO Micro-Cap Growth Conference for investors in December of each
year. This year's conference will feature presentations by over 225
publicly-traded companies and is expected to attract more than 1,000
attendees.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development
company specializing in oncology. CytRx currently is focused on the
clinical development of aldoxorubicin (formerly known as INNO-206), its
improved version of the widely used chemotherapeutic agent doxorubicin.
CytRx is conducting a global Phase 2b clinical trial with aldoxorubicin
as a treatment for soft tissue sarcomas, has completed its Phase 1b/2
clinical trial primarily in the same indication and a Phase 1b study of
aldoxorubicin in combination with doxorubicin in patients with advanced
solid tumors, and has completed a Phase 1b pharmacokinetics clinical
trial in patients with metastatic solid tumors. CytRx plans to initiate
under a special protocol assessment a potential pivotal Phase 3 global
trial with aldoxorubicin as a therapy for patients with soft tissue
sarcomas whose tumors have progressed following treatment with
chemotherapy. CytRx also has initiated a Phase 2 clinical trial with
aldoxorubicin in patients with late-stage glioblastoma (brain cancer)
and is initiating a Phase 2 clinical trial for AIDS-related Kaposi’s
sarcoma. CytRx plans to expand its pipeline of oncology candidates based
on a linker platform technology that can be utilized with multiple
chemotherapeutic agents and may allow for greater concentration of drug
at tumor sites. CytRx also has rights to two additional drug candidates,
tamibarotene and bafetinib. CytRx completed its evaluation of bafetinib
in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic
lymphocytic leukemia (B-CLL), and plans to seek a partner for further
development of bafetinib. For more information about CytRx Corporation,
visit www.cytrx.com.
Copyright Business Wire 2013